• Health & Medicine

Immunotherapy drug approved for head and neck cancer

Some people with head and neck cancer will now have access to the immunotherapy drug pembrolizumab (Keytruda) on the NHS in England.    Some people with head and neck cancer will now have access to the immunotherapy drug pembrolizumab (Keytruda) on the NHS in England.   

26 October 2020

• Health & Medicine

GPs say elderly are not seeking help for potential cancer symptoms

53% of GPs say they are concerned that fewer older adults are contacting them with symptoms compared to before the pandemic, according to new findings 53% of GPs say they are concerned that fewer older adults are contacting them with symptoms compared to before the pandemic, according to new findings

23 October 2020

• Science & Technology

UK could lose up to £7.8 billion of medical research funding because of COVID-19 pandemic 

New figures suggest that the UK could lose up to £7.8 billion of investment in life-saving research by 2027 because of the COVID-19 pandemic. New figures suggest that the UK could lose up to £7.8 billion of investment in life-saving research by 2027 because of the COVID-19 pandemic.

23 October 2020

• Science & Technology
• Health & Medicine

Scientists develop new precision medicine approach for pancreatic cancer

Scientists from the University of Glasgow are developing new ways to predict who will respond to drugs targeting damaged DNA in pancreatic cancer.  Scientists from the University of Glasgow are developing new ways to predict who will respond to drugs targeting damaged DNA in pancreatic cancer. 

12 October 2020

• Health & Medicine
• Science & Technology

Vital rethinking in cancer early detection needed to save lives

The Cancer Research UK Roadmap sets out a plan to overcome the challenges hampering early detection of cancer. The Cancer Research UK Roadmap sets out a plan to overcome the challenges hampering early detection of cancer.

6 October 2020

• Health & Medicine

New drug targeting high-risk children’s cancer is ready for trials

A new drug that has passed safety tests in adults is likely to be effective against the aggressive childhood cancer neuroblastoma. A new drug that has passed safety tests in adults is likely to be effective against the aggressive childhood cancer neuroblastoma.

5 October 2020

• Health & Medicine

HPV vaccine reduces cervical cancer risk

Long awaited study results have confirmed that the quadrivalent human papillomavirus (HPV) vaccine substantially reduces invasive cervical cancer risk.   Long awaited study results have confirmed that the quadrivalent human papillomavirus (HPV) vaccine substantially reduces invasive cervical cancer risk.  

1 October 2020

• Charity News

Cancer Research UK charity Christmas cards now available 

100% of the profits from all sales on our online shop go towards our life-saving research. 100% of the profits from all sales on our online shop go towards our life-saving research.

17 September 2020

• Health & Medicine

Lung cancer risks becoming ‘forgotten disease’ of the coronavirus pandemic  

At least 14,000 fewer people have been urgently referred for lung cancer tests since March.  At least 14,000 fewer people have been urgently referred for lung cancer tests since March. 

17 September 2020

• Health & Medicine

Targeted drug for lung cancer approved for NHS use in England

The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer. The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.

11 September 2020

• Health & Medicine

Myeloma maintenance treatment not recommended on NHS in England

Cancer drug lenalidomide receives an initial rejection to treat some adults with myeloma following a stem cell transplant. Cancer drug lenalidomide receives an initial rejection to treat some adults with myeloma following a stem cell transplant.

10 September 2020

• Health & Medicine

Rare bowel cancer treatment combo gets initial no for NHS use in England  

A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence. A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence.

4 September 2020